Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the effectiveness of combining thalidomide and
chemoembolization in treating patients who have liver cancer that cannot be removed by
surgery. Thalidomide may stop the growth of liver cancer by stopping blood flow to the tumor.
Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping
chemotherapy drugs near the tumor. Combining thalidomide with chemoembolization may kill more
tumor cells.